Instalab
logoInstalab

A. Phagocytophilum IgG Screen

Blood Test
Check for evidence of a tick-borne infection after an unexplained fever.
4.9 (4,913 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a A. Phagocytophilum IgG Screen test?

This test is most useful if any of these apply to you.

Sick After Time Outdoors
A fever after possible tick exposure warrants prompt assessment; this screen can contribute to the investigation.
Still Sick Despite an Early Negative
Antibodies may take time to appear. Follow-up IgG testing and whole-blood PCR can help evaluate a compatible illness.
Recovering From an Unexplained Fever
Paired IgG testing may help establish the cause of a recent illness after outdoor exposure.
Immunocompromised With a Recent Fever
Tick-related illness can be more severe with a weakened immune system. Prompt assessment matters even if this screen is negative.

About A. Phagocytophilum IgG Screen

A fever after time in tick habitat can be anaplasmosis even when your first antibody result is negative. This screen looks for an immune response to Anaplasma phagocytophilum. Its usefulness depends on when you became ill and whether the result agrees with your symptoms and other findings.

A positive screen can reflect a current infection, a past infection or antibodies that react with a related organism. It can't establish when an infection happened or prove that a recent tick bite transmitted it.

What the Test Measures

IgG stands for immunoglobulin G. After an infection resolves, these antibodies can stay in circulation for weeks to years, and the duration varies from person to person. Anaplasma phagocytophilum lives inside neutrophils. These white blood cells help fight infection. The illness the bacterium causes is called human granulocytic anaplasmosis, or HGA.

This screen detects IgG antibodies in serum using indirect immunofluorescence, or IFA. Serum is the liquid left after blood clots. The lab exposes diluted serum to cells containing the bacterium and uses a fluorescent reagent to reveal antibody binding under a microscope.

The screen reports whether antibodies are detected. A reactive sample can undergo a separate titer measurement, which records how far the serum can be diluted while the reaction remains visible. That titer is an estimate of antibody reactivity, not an exact antibody concentration. The screen itself has no numerical level to trend.

The CDC treats IgG IFA as the reference standard for confirming anaplasmosis with antibody testing, especially when titers from an illness and recovery are compared. It is insensitive in the first week of illness and becomes highly sensitive two to three weeks after symptoms start.

Human Granulocytic Anaplasmosis

The illness usually starts with fever, headache, muscle aches and a general sense of being unwell. Blood work often shows low platelets, low white cell counts and raised liver enzymes. Severe illness can include kidney failure, respiratory failure and failure of several organs.

In U.S. surveillance from 2008 through 2012, about three in a thousand reported cases with known outcomes were fatal. Older age, a weakened immune system, conditions such as diabetes and delayed treatment increase the risk of severe illness. This risk comes from the infection; an antibody result doesn't grade its severity.

In a medical-record study of 465 people with PCR-confirmed anaplasmosis, hospitalized people were more often older or immunocompromised and had more underlying illness. Only about a quarter had all three commonly described laboratory findings together: low white cells, low platelets and raised liver enzymes. Missing one part of that pattern is common.

How Common a Positive Result Is

Antibodies also turn up in healthy people. Their frequency varies with geography, past exposure and the assay used. Studies that count positive antibody results don't necessarily count confirmed infections.

Who Was StudiedHow Antibodies Were AssessedWhat They Found
People in 56 studies worldwidePooled antibody surveys across different populations and testing approachesAntibody positivity was about 5% in healthy populations and 14% in groups considered at higher risk
301 healthy blood donors in western NorwaySerum IgG measured by indirect immunofluorescenceAbout one in six had a positive result
About 10,000 U.S. military personnelELISA screening followed by Western blot testing, different methods from this IFA screenAbout 2.6% were reactive by ELISA, while 0.11% were positive by Western blot

The Norwegian study measured the same antibody class in serum by IFA. The global review pooled broader antibody evidence, and the military study used different assays. Their percentages cannot be used as the accuracy of this screen or as your personal chance of infection. The large difference between the military study's two methods also shows why a reactive screening result needs context.

Exposure Without Illness

A study in Sweden and the Åland Islands followed 90 people after tick bites using serum IgG IFA. Thirty had been bitten by ticks carrying Anaplasma. Only one participant developed a fourfold antibody rise over three months, and that person reported no symptoms. Their submitted tick had tested negative for Anaplasma, so the antibody change couldn't be attributed to transmission from a known infected tick. This small study doesn't establish the risk from an infected tick in every region.

Why Early Tests Come Back Negative

The immune response takes time. IgG IFA is frequently negative during the first week of illness, when the bacterium may already be detectable by a whole-blood PCR test. PCR looks for bacterial DNA. Only about a quarter to a half of people have detectable antibodies when they first seek care.

In a small New York study of infections confirmed by PCR and culture, IgG IFA detected antibodies in only around half of the samples taken during illness but in nearly all recovery samples. The study supports comparing illness and recovery samples, but its small size and selected cases limit how precisely it estimates performance in everyday use.

When Results Can Be Misleading

  • Past infection: antibodies can remain detectable long after recovery. A positive result doesn't establish that bacteria are still present.
  • Cross-reactions: antibodies to related organisms can react in this assay, especially Ehrlichia species and the bacteria that cause Rocky Mountain spotted fever and Q fever. A single screen may not identify which organism caused the response.
  • Other tick-borne infections: neoehrlichiosis is another tick-borne bacterial infection. About one in five affected people in one study had low-level Anaplasma-reactive antibodies. These can reflect cross-reactivity, previous exposure or a true co-infection, so they don't by themselves prove a simultaneous Anaplasma infection.
  • Differences in IFA preparations: small human studies in Japan found that antibody reactivity changed depending on how the bacteria used in the assay were grown. Results can also differ between laboratories, so a small difference between titers need not represent a biological change.
  • Early treatment: in Rocky Mountain spotted fever, very early antibiotics sometimes reduce or delay antibody production. For anaplasmosis the effect is uncertain: one study found doxycycline in the first week didn't affect whether antibodies formed, although they disappeared sooner afterward.
  • Specimen quality: blood-cell damage, contamination or excess fat in the serum sample can also affect testing.
  • A qualitative result: two results reported as detected don't show whether antibody reactivity rose or fell. Demonstrating a fourfold rise requires separately reported IFA titers.

Changes Between Samples

A change from not detected to detected can support a recent immune response when the illness and timing fit. A fourfold rise in paired IgG IFA titers provides stronger evidence of recent infection. Those are related findings, but a change in the screen result alone doesn't establish a fourfold rise.

Over longer periods, persistent positivity can reflect immune memory. Antibody results are not a reliable way to measure treatment success or decide whether an infection has cleared.

What Moves This Biomarker

Evidence-backed interventions that affect your A. Phagocytophilum IgG Screen level

↑ Increase
Forestry work with repeated tick exposure
Repeated tick exposure increases the opportunity for infection and a detectable IgG response. In a small Polish study using serum IgG IFA, forestry workers tested positive more often than urban blood donors. A larger study of 478 Polish forestry rangers found nearly identical antibody rates in mostly outdoor and mostly indoor workers, so occupational exposure doesn't consistently predict a positive result.
LifestyleModest Evidence

Frequently Asked Questions

Panels containing A. Phagocytophilum IgG Screen

A. Phagocytophilum IgG Screen is included in these pre-built panels.

References

22 studies
  1. Centers for Disease Control and PreventionCDC2024
  2. Centers for Disease Control and PreventionCDC2024
  3. Centers for Disease Control and PreventionCDC2025
  4. Holly M. Biggs, Casey Barton Behravesh, Kristy K. Bradley, F. Scott Dahlgren, Naomi a. Drexler, J. Stephen Dumler, Scott M. Folk, Cecilia Y. Kato, R. Ryan Lash, Michael L. Levin, Robert F. Massung, Robert B. Nadelman, William L. Nicholson, Christopher D. Paddock, Bobbi S. Pritt, Marc S. TraegerMMWR Recommendations and Reports2016

A. Phagocytophilum IgG Screen Testing Option

Anaplasma Phagocytophilum Antibodies

$345

See whether a tick may have left you with anaplasmosis, and whether the exposure looks recent or long past.

Includes 4 biomarkers:
A. Phagocytophilum IgG ScreenA. Phagocytophilum IgM ScreenA. Phagocytophilum IgG TiterA. Phagocytophilum IgM Titer
FSA/HSA eligible
No Rx needed
HIPAA compliant